Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
IRVINE, Calif., Aug. 30, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (Nasdaq:SVA). Investors who purchased or otherwise acquired Sinovac shares from April 30, 2013 through May 16, 2017, inclusive (the “Class Period”), should contact the firm by September 1, 2017, the lead plaintiff motion deadline.
If you purchased shares of Sinovac during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the Complaint, throughout the Class Period, Sinovac made false and/or misleading statements and/or failed to disclose: that Chairman and CEO Weidong Yin bribed a member of the Chinese Food and Drug Administration to assist Sinovac’s vaccine clinical trial and approval; that such conduct would subject it to heightened regulatory scrutiny; and that as a result, Sinovac’s public statements were materially false and misleading at all relevant times. When this information reached the public, Sinovac’s stock price fell materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may be considered Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
